This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Patterson Companies' (PDCO) Unit Completes Miller Vet Buyout
by Zacks Equity Research
Patterson Companies' (PDCO) subsidiary completes acquisition of Miller Vet, which is likely to bolster its Animal Health's presence in the companion animal market.
Reasons to Add HealthEquity Stock (HQY) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity (HQY) on its slew of buyouts and strength in HSA.
Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia
by Zacks Equity Research
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.
Ecolab (ECL) to Aid Life Sciences Industry With New Offering
by Zacks Equity Research
Ecolab (ECL) unveils new virtual service offering to help the life sciences industry to address cleaning and disinfection challenges.
Veeva Systems' (VEEV) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Veeva Systems Inc. (VEEV).
Looking for a Growth Stock? 3 Reasons Why Veeva (VEEV) is a Solid Choice
by Zacks Equity Research
Veeva (VEEV) could produce exceptional returns because of its solid growth attributes.
Veeva (VEEV) Customer Intelligence Platform Reaches New Areas
by Zacks Equity Research
Veeva Link's expansion across 11 new therapeutic areas to drive engagement for Veeva's (VEEV) partner companies with key experts.
Why You Should Add Veeva Systems (VEEV) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
HealthEquity (HQY) Q1 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
HealthEquity (HQY) delivers solid growth in HSAs along with recording robust Interchange revenues in the first quarter of fiscal 2022.
BD (BDX) Solidifies Foothold in Healthcare Cybersecurity
by Zacks Equity Research
BD's (BDX) authorization as a CNA is expected to allow it to provide customers with timely information about vulnerabilities in BD products available globally.
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
by Zacks Equity Research
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
Why Veeva (VEEV) Isn't Done Growing Earnings Yet
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Veeva (VEEV).
Strength Seen in Veeva (VEEV): Can Its 10.1% Jump Turn into More Strength?
by Zacks Equity Research
Veeva (VEEV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both its segments.
Veeva Systems (VEEV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 16.67% and 5.90%, respectively, for the quarter ended April 2021. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems' (VEEV) Cloud Offerings Aid Drug Development
by Zacks Equity Research
Veeva Systems' (VEEV) Cloud applications help in simplifying and accelerating drug development on an industry-wide basis.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Veeva Systems (VEEV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Veeva (VEEV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veeva Systems (VEEV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $247.92, marking a -1.5% move from the previous day.
Veeva (VEEV) Enhances Clinical Trial Management via Vault CTMS
by Zacks Equity Research
Veeva's (VEEV) Vault CTMS application is expected to aid global organizations to advance study execution while ensuring compliance.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $252.81 in the latest trading session, marking a +1.47% move from the prior day.
3 Tech Stocks to Buy Now After Disappointing Jobs Data
by Benjamin Rains
Clearly, hiring could rebound in May, but let's dive into three technology stocks that aren't banking on a swift economic recovery following the disappointing jobs data...
Veeva Systems (VEEV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $282.01 in the latest trading session, marking a -1.58% move from the prior day.